Search research articles
Contact Us
Filters
Showing results (1-10 of 149) with videos related to
Page
of 15
Sort By:
The Lancet. Oncology
|
January 21, 2018
Inotuzumab ozogamicin in older patients with acute lymphoblastic leukaemia: premises and promises
Carmelo Rizzari
Blood
|
March 29, 2014
Shedding light on the asparaginase galaxy
Carmelo Rizzari
The Lancet. Oncology
|
November 10, 2015
Still trying to pick the best asparaginase preparation
Carmelo Rizzari
Pediatric Blood & Cancer
|
June 23, 2009
Tailoring treatment strategy for acute promyelocytic leukemia in low-income countries
Carmelo Rizzari, Andrea Biondi
British Journal of Clinical Pharmacology
|
May 21, 2025
Reply to: Methotrexate toxicity and glucarpidase: A call for dose optimization. Koppen A, et al. Br J Clin Pharmacol. 2025;91(5):1289-1292 doi:10.1002/bcp.70044
Carmelo Rizzari, Stefan Schwartz
Leukemia & Lymphoma
|
January 15, 2015
Asparaginase pharmacokinetics and implications of therapeutic drug monitoring
Barbara Asselin, Carmelo Rizzari
Haematologica
|
July 20, 2023
Back to the future: the amazing journey of the therapeutic anti-leukemia enzyme asparaginase <i>Erwinia chrysanthemi</i>
Wing H Tong, Carmelo Rizzari
Expert Review of Hematology
|
March 10, 2026
<i>"Per aspera ad astra"</i>: the transformative contribution of glucarpidase to the improved management of delayed methotrexate elimination after high dose therapy
Nicolò Peccatori, Stefan Schwartz, Carmelo Rizzari
Expert Review of Anticancer Therapy
|
September 21, 2011
Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease
Carmelo Rizzari, Giovanni Cazzaniga, Tiziana Coliva, et al.
Current Opinion in Oncology
|
February 6, 2013
Optimizing asparaginase therapy for acute lymphoblastic leukemia
Carmelo Rizzari, Valentino Conter, Jan Starý, et al.
Page
of 15
Search research articles
Search
Showing results (1-10 of 149) with videos related to
Sort By:
Page
of 15
The Lancet. Oncology
|
January 21, 2018
Inotuzumab ozogamicin in older patients with acute lymphoblastic leukaemia: premises and promises
Carmelo Rizzari
Blood
|
March 29, 2014
Shedding light on the asparaginase galaxy
Carmelo Rizzari
The Lancet. Oncology
|
November 10, 2015
Still trying to pick the best asparaginase preparation
Carmelo Rizzari
Pediatric Blood & Cancer
|
June 23, 2009
Tailoring treatment strategy for acute promyelocytic leukemia in low-income countries
Carmelo Rizzari, Andrea Biondi
British Journal of Clinical Pharmacology
|
May 21, 2025
Reply to: Methotrexate toxicity and glucarpidase: A call for dose optimization. Koppen A, et al. Br J Clin Pharmacol. 2025;91(5):1289-1292 doi:10.1002/bcp.70044
Carmelo Rizzari, Stefan Schwartz
Leukemia & Lymphoma
|
January 15, 2015
Asparaginase pharmacokinetics and implications of therapeutic drug monitoring
Barbara Asselin, Carmelo Rizzari
Haematologica
|
July 20, 2023
Back to the future: the amazing journey of the therapeutic anti-leukemia enzyme asparaginase <i>Erwinia chrysanthemi</i>
Wing H Tong, Carmelo Rizzari
Expert Review of Hematology
|
March 10, 2026
<i>"Per aspera ad astra"</i>: the transformative contribution of glucarpidase to the improved management of delayed methotrexate elimination after high dose therapy
Nicolò Peccatori, Stefan Schwartz, Carmelo Rizzari
Expert Review of Anticancer Therapy
|
September 21, 2011
Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease
Carmelo Rizzari, Giovanni Cazzaniga, Tiziana Coliva, et al.
Current Opinion in Oncology
|
February 6, 2013
Optimizing asparaginase therapy for acute lymphoblastic leukemia
Carmelo Rizzari, Valentino Conter, Jan Starý, et al.
Page
of 15